Centessa Pharmaceuticals PLC ADR (NASDAQ:CNTA) — Stock Price
Centessa Pharmaceuticals PLC ADR (NASDAQ:CNTA) is currently trading at $39.43 USD, down 0.10% today. Over the past 52 weeks, shares have ranged between $11.86 and $39.86. This page tracks Centessa Pharmaceuticals PLC ADR's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see CNTA stock market capitalisation.
Centessa Pharmaceuticals PLC ADR (CNTA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Centessa Pharmaceuticals PLC ADR's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Centessa Pharmaceuticals PLC ADR Income Statement — Revenue, Profit & Earnings by Year
Centessa Pharmaceuticals PLC ADR's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $15.00 Million | $0.00 | $6.85 Million | $0.00 | $0.00 |
| Cost of Revenue | — | $942.40K | $813.14K | $130.92K | — |
| Gross Profit | $15.00 Million | $-942.40K | $6.85 Million | $-131.00K | — |
| Research & Development | $172.22 Million | $150.24 Million | $124.41 Million | $155.08 Million | $9.30 Million |
| SG&A | $50.47 Million | $50.81 Million | $53.73 Million | $55.20 Million | $1.14 Million |
| Total Operating Expenses | $222.69 Million | $201.06 Million | $178.14 Million | $212.26 Million | $10.44 Million |
| Operating Income | $-207.69 Million | $-201.06 Million | $-171.28 Million | $-212.26 Million | $-10.44 Million |
| EBITDA | $-183.33 Million | $-221.88 Million | $-165.43 Million | $-209.55 Million | $-10.29 Million |
| EBIT | $-184.25 Million | $-222.82 Million | $-166.24 Million | $-209.68 Million | $-10.44 Million |
| Interest Expense | $11.46 Million | $10.09 Million | $9.91 Million | $7.28 Million | $378.00K |
| Income Before Tax | $-195.71 Million | $-232.91 Million | $-176.14 Million | $-216.95 Million | $-10.66 Million |
| Income Tax Expense | $1.82 Million | $2.84 Million | $-25.06 Million | $-747.00K | $378.00K |
| Net Income | $-197.53 Million | $-235.76 Million | $-151.09 Million | $-216.21 Million | $-10.66 Million |
Centessa Pharmaceuticals PLC ADR Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Centessa Pharmaceuticals PLC ADR's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $687.50 Million | $576.80 Million | $360.25 Million | $444.31 Million | $629.63 Million |
| Total Current Assets | $367.88 Million | $536.41 Million | $315.09 Million | $437.75 Million | $628.77 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $233.28 Million | $98.96 Million | $128.52 Million | $0.00 | — |
| Net Receivables | $60.34 Million | $45.30 Million | $39.15 Million | $26.72 Million | $16.81 Million |
| Inventory | — | — | $1.00 | $-29.99 Million | $-17.81 Million |
| Property, Plant & Equipment | — | — | — | $1.17 Million | $162.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $160.63 Million | $175.25 Million | $124.00 Million | $108.14 Million | $138.08 Million |
| Total Current Liabilities | $42.94 Million | $58.00 Million | $39.38 Million | $38.34 Million | $24.64 Million |
| Long-term Debt | $110.09 Million | $108.94 Million | $75.70 Million | $69.80 Million | $75.70 Million |
| Net Debt | $-53.73 Million | $-266.00 Million | $-43.44 Million | $-323.84 Million | $-519.38 Million |
| Total Stockholder Equity | $526.86 Million | $401.55 Million | $236.24 Million | $336.17 Million | $491.55 Million |
| Retained Earnings | $-1.19 Billion | $-988.70 Million | $-752.95 Million | $-601.86 Million | $-385.65 Million |
Centessa Pharmaceuticals PLC ADR Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Centessa Pharmaceuticals PLC ADR generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-193.82 Million | $-142.06 Million | $-160.34 Million | $-200.55 Million | $-136.14 Million |
| Capital Expenditures | $371.00K | $34.00K | $169.00K | $1.14 Million | $185.98K |
| Free Cash Flow | $-194.19 Million | $-142.09 Million | $-160.51 Million | $-201.68 Million | $-136.33 Million |
| Investing Cash Flow | $-418.53 Million | $31.27 Million | $-127.00 Million | $-931.00K | $63.25 Million |
| Financing Cash Flow | $291.53 Million | $364.75 Million | $21.12 Million | $457.00K | $660.07 Million |
| Dividends Paid | — | — | — | — | $660.12K |
| Stock-Based Compensation | $30.96 Million | $33.55 Million | $29.39 Million | $24.96 Million | $14.85 Million |
| Depreciation | $921.00K | $942.00K | $810.00K | $131.00K | $33.99K |
| Change in Cash | $-321.27 Million | $255.19 Million | $-265.61 Million | $-201.44 Million | $590.08 Million |
Centessa Pharmaceuticals PLC ADR Earnings History — EPS Actual vs. Analyst Estimates
Track Centessa Pharmaceuticals PLC ADR's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 18, 2026 | -0.52 | -0.38 | -35.49% |
| Mar 26, 2026 | -0.48 | -0.38 | -24.90% |
| Nov 05, 2025 | -0.41 | -0.39 | -5.13% |
| Aug 12, 2025 | -0.38 | -0.33 | -15.26% |
| May 14, 2025 | -0.20 | -0.36 | +44.44% |
| Mar 24, 2025 | -0.84 | -0.42 | -100.00% |
| Nov 12, 2024 | -0.37 | -0.40 | +6.64% |
| Aug 13, 2024 | -0.40 | -0.39 | -2.56% |